MX2019003943A - Farmaco eficaz para un metodo linfogeno de administracion de farmaco. - Google Patents

Farmaco eficaz para un metodo linfogeno de administracion de farmaco.

Info

Publication number
MX2019003943A
MX2019003943A MX2019003943A MX2019003943A MX2019003943A MX 2019003943 A MX2019003943 A MX 2019003943A MX 2019003943 A MX2019003943 A MX 2019003943A MX 2019003943 A MX2019003943 A MX 2019003943A MX 2019003943 A MX2019003943 A MX 2019003943A
Authority
MX
Mexico
Prior art keywords
drug
lymphogenous
effective
administrating method
administered
Prior art date
Application number
MX2019003943A
Other languages
English (en)
Inventor
Kodama Tetsuya
Mori Shiro
Nohara Go
Original Assignee
Univ Tohoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tohoku filed Critical Univ Tohoku
Publication of MX2019003943A publication Critical patent/MX2019003943A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona una composición farmacéutica conveniente para administración de fármacos anticáncer en nodos linfáticos por medio de sistemas de suministro de fármaco linfático; una composición farmacéutica para el tratamiento terapéutico o profiláctico de cáncer a ser administrada en nodos linfáticos, comprende al menos un fármaco anticáncer seleccionado del grupo que consiste en antimetabolitos y alcaloides vegetales anticáncer como un principio activo.
MX2019003943A 2016-10-05 2017-08-31 Farmaco eficaz para un metodo linfogeno de administracion de farmaco. MX2019003943A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016197614 2016-10-05
PCT/JP2017/031483 WO2018066278A1 (ja) 2016-10-05 2017-08-31 リンパ行性薬剤投与法で有効な薬剤

Publications (1)

Publication Number Publication Date
MX2019003943A true MX2019003943A (es) 2019-09-18

Family

ID=61831759

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003943A MX2019003943A (es) 2016-10-05 2017-08-31 Farmaco eficaz para un metodo linfogeno de administracion de farmaco.

Country Status (12)

Country Link
US (2) US11559526B2 (es)
EP (1) EP3524269B1 (es)
JP (1) JP6960637B2 (es)
KR (1) KR102431011B1 (es)
CN (1) CN110022899A (es)
AU (1) AU2017340350B9 (es)
BR (1) BR112019006949A2 (es)
CA (1) CA3039442C (es)
MX (1) MX2019003943A (es)
RU (1) RU2759640C2 (es)
TW (1) TWI754666B (es)
WO (1) WO2018066278A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60190769A (ja) * 1984-03-09 1985-09-28 Sagami Chem Res Center ５−フルオロウラシルの製造方法
JP2003521591A (ja) * 1999-10-22 2003-07-15 ザ、プロクター、エンド、ギャンブル、カンパニー エチレン−プロピレンランダムコポリマーの構成繊維により形成された不織布を用いた不織布複合積層体
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
BRPI0608173A2 (pt) * 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
CN101045163B (zh) * 2006-03-29 2011-03-30 重庆莱美药业股份有限公司 一种高分子抗癌前药及其制备方法和用途
KR20100062990A (ko) * 2007-06-12 2010-06-10 크리스틴 알렌 국소적 약물전달을 위한 주사용 고분자-지질 배합물
EP2025333A1 (en) * 2007-08-14 2009-02-18 Pharmatex Italia Srl Injectable pharmaceutical formulation of taxoids
EP2279006B1 (en) 2008-04-22 2014-10-22 FIDIA FARMACEUTICI S.p.A. Therapeutic use of pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias
EP2875814B1 (en) * 2012-07-19 2018-08-22 FUJIFILM Corporation Liquid composition containing taxane-based active ingredient, process for producing same, and liquid medicinal preparation
KR101683635B1 (ko) * 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
EP3677283A4 (en) * 2017-08-31 2021-05-12 Tohoku University APPROPRIATE AREA OF OSMOTIC PRESSURE OF A SOLUTION WITH MEDICINAL PRODUCT EFFECTIVE IN LYMPHODIC DELIVERY SYSTEM

Also Published As

Publication number Publication date
TWI754666B (zh) 2022-02-11
RU2019109965A (ru) 2020-11-06
EP3524269B1 (en) 2024-02-21
CA3039442A1 (en) 2018-04-12
EP3524269A4 (en) 2020-06-17
AU2017340350A1 (en) 2019-05-02
KR102431011B1 (ko) 2022-08-09
JPWO2018066278A1 (ja) 2019-07-18
AU2017340350B9 (en) 2023-02-09
KR20190064570A (ko) 2019-06-10
EP3524269A1 (en) 2019-08-14
RU2019109965A3 (es) 2020-12-14
CN110022899A (zh) 2019-07-16
AU2017340350B2 (en) 2022-12-22
CA3039442C (en) 2023-07-04
US20200038400A1 (en) 2020-02-06
US20230119275A1 (en) 2023-04-20
WO2018066278A1 (ja) 2018-04-12
BR112019006949A2 (pt) 2019-07-02
RU2759640C2 (ru) 2021-11-16
JP6960637B2 (ja) 2021-11-05
TW201813668A (zh) 2018-04-16
US11559526B2 (en) 2023-01-24

Similar Documents

Publication Publication Date Title
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
MX2018003096A (es) Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.
HRP20191265T8 (hr) Supstituirani 2-tiokso-imidazolidin-4-oni i njihovi spiro analozi, aktivni anti-kancerogeni sastojak, farmaceutska kompozicija, medicinski preparat, metoda za liječenje raka prostate
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2017003561A (es) Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
PH12016501527A1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
NZ726131A (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2019003943A (es) Farmaco eficaz para un metodo linfogeno de administracion de farmaco.
AU2017276588A1 (en) Physiologically balanced injectable formulations of fosnetupitant
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
MX2020006886A (es) Sistema para suministro de medicamento.
WO2019098691A3 (ko) 음이온성 약물 함유 약제학적 조성물의 동결건조 조성물 및 방법
PH12016502540A1 (en) Pharmaceutical dosage forms
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
RU2017140779A (ru) Композиции для лечения рака
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
IN2013MU03370A (es)
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
MX2020013385A (es) Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion.
UA104615U (uk) Спосіб лікування токсокарозу
WO2016164719A3 (en) Methods used to treat cancer